Fulvestrant injection is used to treat hormone-receptor (HR) positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women who haven’t been previously treated with other medicines. It is also used to treat HR-positive breast cancer that has progressed or got worse after hormonal therapy.
Fulvestrant injection is also used together with ribociclib to treat HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women who haven’t been previously treated with other medicines or whose cancer has progressed or gotten worse after hormonal therapy.
Fulvestrant injection is also used together with palbociclib or abemaciclib to treat HR-positive, HER2-negative advanced or metastatic (cancer that has spread) breast cancer in women who have received hormonal therapy.
Many breast cancer tumours will grow when estrogen is available in your body. This medicine obstructs the effects of estrogen in the body. As a result, the amount of estrogen that the tumour is exposed to is decreased, which will limit the growth of the tumour.
This medication is only available under the prescription of your doctor.
The product is available in the following dosing forms: